The closing price of Alpine Immune Sciences Inc (NASDAQ: ALPN) was $35.38 for the day, down -1.53% from the previous closing price of $35.93. In other words, the price has decreased by -$0.55 from its previous closing price. On the day, 1138994 shares were traded. ALPN stock price reached its highest trading level at $37.17 during the session, while it also had its lowest trading level at $35.29.
Ratios:
Our analysis of ALPN’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.81 and its Current Ratio is at 3.81. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.06.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wolfe Research on February 15, 2024, initiated with a Outperform rating and assigned the stock a target price of $44.
On October 18, 2023, Berenberg started tracking the stock assigning a Buy rating and target price of $18.
On October 17, 2023, Berenberg started tracking the stock assigning a Buy rating and target price of $18.Berenberg initiated its Buy rating on October 17, 2023, with a $18 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 26 ’24 when Rickey James Paul sold 117,764 shares for $23.32 per share. The transaction valued at 2,745,830 led to the insider holds 0 shares of the business.
Rickey James Paul sold 236 shares of ALPN for $5,192 on Jan 25 ’24. The insider now owns 0 shares after completing the transaction at $22.00 per share. On Dec 28 ’23, another insider, ORBIMED ADVISORS LLC, who serves as the Director of the company, sold 1,364,849 shares for $18.35 each. As a result, the insider received 25,049,034 and left with 264,315 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALPN now has a Market Capitalization of 2.36B and an Enterprise Value of 2.17B. For the stock, the TTM Price-to-Sale (P/S) ratio is 75.29 while its Price-to-Book (P/B) ratio in mrq is 10.79. Its current Enterprise Value per Revenue stands at 70.52 whereas that against EBITDA is -38.99.
Stock Price History:
Over the past 52 weeks, ALPN has reached a high of $39.27, while it has fallen to a 52-week low of $6.39. The 50-Day Moving Average of the stock is 26.87, while the 200-Day Moving Average is calculated to be 16.17.
Shares Statistics:
ALPN traded an average of 1.03M shares per day over the past three months and 1.08M shares per day over the past ten days. A total of 65.54M shares are outstanding, with a floating share count of 47.04M. Insiders hold about 28.22% of the company’s shares, while institutions hold 68.33% stake in the company. Shares short for ALPN as of Feb 15, 2024 were 4.03M with a Short Ratio of 3.89, compared to 2.41M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.15% and a Short% of Float of 10.03%.
Earnings Estimates
The firm’s stock currently is rated by 7 analysts. On average, analysts expect EPS of -$0.34 for the current quarter, with a high estimate of -$0.2 and a low estimate of -$0.58, while EPS last year was -$0.41. The consensus estimate for the next quarter is -$0.36, with high estimates of -$0.26 and low estimates of -$0.55.
Analysts are recommending an EPS of between -$0.98 and -$1.33 for the fiscal current year, implying an average EPS of -$1.1. EPS for the following year is -$1.49, with 8 analysts recommending between -$0.77 and -$2.2.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 6 analysts. It ranges from a high estimate of $12M to a low estimate of $3M. As of the current estimate, Alpine Immune Sciences Inc’s year-ago sales were $2.78M, an estimated increase of 227.80% from the year-ago figure.
A total of 8 analysts have provided revenue estimates for ALPN’s current fiscal year. The highest revenue estimate was $40M, while the lowest revenue estimate was $30M, resulting in an average revenue estimate of $35.71M. In the same quarter a year ago, actual revenue was $30.06M, up 18.80% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $27.36M in the next fiscal year. The high estimate is $64.5M and the low estimate is $10M. The average revenue growth estimate for next year is down -23.40% from the average revenue estimate for this year.
